Robert B. Bhisitkul MD
Professor, Ophthalmology, UCSF School of Medicine
Join to View Full Profile
400 Parnassus AveSan Francisco, CA 94143
Phone+1 415-353-2402
Fax+1 415-353-2713
Dr. Bhisitkul is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts Eye and Ear/Harvard Medical SchoolResidency, Ophthalmology, 1993 - 1996
New York Medical College at St Vincent's Hospital and Medical Center of New YorkInternship, Transitional Year, 1992 - 1993
Stanford University School of MedicineClass of 1992
Certifications & Licensure
CA State Medical License 1998 - 2026
MA State Medical License 1996 - 1999
American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery Start of enrollment: 2008 Apr 01
- Seven Year Update of Macular Degeneration Patients Start of enrollment: 2010 Dec 01
Publications & Presentations
PubMed
- 3 citationsSubretinal hyperreflective material in regions of atrophy and fibrosis in eyes with neovascular age-related macular degeneration.Sophiana Lindenberg, Muneeswar G Nittala, Aditya Verma, Malinda E C Fitzgerald, Swetha B Velaga
Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie. 2025-02-01 - 2 citationsHeterogeneity in disease activity, frequency of treatments, and visual outcomes among patients with retinal vein occlusion: relationship between injection need and vis...Robert B Bhisitkul, Peter A Campochiaro, Steven Blotner, Carlos Quezada-Ruiz, Mimi Liu
The British Journal of Ophthalmology. 2024-08-22 - 3 citationsClinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration (nAMD): phase 2 trials in treatment-naïve and anti-VEGF pretreated patients.Daniel S Pereira, Raj K Maturi, Kazumasa Akita, Vinaya Mahesh, Robert B Bhisitkul
Eye. 2024-04-01
Press Mentions
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular EdemaMarch 23rd, 2023- UNITY Biotechnology’s Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the EyeOctober 11th, 2022
- UNITY Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of UBX1325 in Phase 1 Study of Patients with Advanced Vascular Eye DiseaseNovember 9th, 2021
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
